Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.48 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.41 |
| ▸ | HTR3B | O95264 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839614 | 0.85 | FLT1 (0.41) | TRPV4FLT1FLT4KDRMEN1 | |
| SCHEMBL29617571 | 0.83 | ALDH1A1 (0.45) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL16795954 | 0.83 | ALDH1A1 (0.45) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL9150373 | 0.79 | TRPV4 (0.42) | TRPV4FLT1FLT4KDRHTR3E | |
| SCHEMBL29636402 | 0.77 | TRPV4 (0.55) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2127233 | 0.77 | TRPV4 (0.55) | TRPV4HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31240957 | 0.76 | CA12 (0.60) | MEN1KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL667942 | 0.76 | CA12 (0.60) | MEN1KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL1833359 | 0.76 | ACHE (0.60) | MEN1KMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL18085326 | 0.75 | ALDH1A1 (0.40) | TRPV4HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321244-B1 | IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-12-21 | — | — | EP | claimed |
| US-8558030-B2 | Process for telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-10-15 | — | — | US | claimed |
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) | 2011-06-09 | — | — | US | claimed |
| EP-2321244-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010019360-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-02-18 | — | — | WO | claimed |
| EP-2321244-B1 | IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-8912346-B2 | Palladium phosphine complexes for the telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8779164-B2 | Phosphine-based catalysts useful for the telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-8558030-B2 | Process for telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130123516-A1 | NOVEL PHOSPHINE-BASED CATALYSTS USEFUL FOR THE TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-05-16 | — | — | US | disclosed |
| EP-2431375-B1 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2537582-A1 | NOVEL PHOSPHINE-BASED CATALYSTS SUITABLE FOR BUTADIENE TELOMERISATION | Dow Global Technologies LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2431375-A2 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120046475-A1 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELEOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2321244-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010019360-A2 | AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137086-A1 | PROCESS FOR TELOMERIZATION OF BUTADIENE | HRH3, HRH4, TELO2 | TRPV4 1183/4885FLT1 4556/4885FLT4 3115/4885 |
| US-20130123516-A1 | NOVEL PHOSPHINE-BASED CATALYSTS USEFUL FOR THE TELOMERIZATION OF BUTADIENE | TERT, TELO2, TPR | TRPV4 2092/4885FLT1 4465/4885FLT4 4305/4885 |
| US-20120046475-A1 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELEOMERIZATION OF BUTADIENE | TTI1, TTI2, PAXBP1 | TRPV4 2719/4885FLT1 4690/4885FLT4 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.